Dextromethorphan and guaifenesin use must be monitored meticulously in people with "very poor metabolizer" CYP2D6 enzyme stages and individuals who are sedated. This mix medication features a large median poisonous dose (TD50) to median effective dose (ED50) ratio (or therapeutic index) in these patients. Effects with the clinical trial found https://chemicalglobe.com/